Research, Incorporated

Walter D Whybrew

Edsel T Bucovaz

John C Morrison

Stanley J Tarnowski, Jr

William C Morrison

A method of detecting cancer in mammals which comprises admixing with a serum sample from said mammal detectably labelled acyl carrier protein and subsequently determining the amount of B-protein-acyl carrier protein complex which is formed.

Cancer detection procedure using an acyl carrier protein

A method of detecting cancer in mammals which comprises precipitating at least a portion of the proteins in a serum sample from a mammal and then measuring the rate at which said precipitated proteins are re-solubilized.

Diagnostic test for the detection of cancer

A process for preparing CoA-SPC Bakers' yeast extract which comprises:

Process for the preparation of CoA-SPC from Bakers' yeast

CoA-SPC Bakers' yeast extract which is substantially free of proteolytic enzymes.

T-factor, CoA-SPC substantially free of proteolytic enzymes and its

A specific type of protein, which has been designated B-protein (Bucovaz-protein), is present in most serum of individuals with cancer. The B-protein interacts with a low molecular weight protein component, which is released by the coenzyme A-synthesizing protein complex (CoA-SPC) of Bakers' yeast during the course of CoA synthesis. This low molecular weight protein, for purposes of identification, is referred to as binding protein. The binding protein has a molecular weight of 10,000 to 15,000. Interaction of radioactively labeled binding protein of CoA-SPC with the B-protein of serum provides a marker for the detection of cancer. Of 3005 serums assayed, which included 908 patients diagnosed as having cancer, the B-protein assay agreed with the clinical diagnosis in more than 89% of the cases.

Growing community of inventors

Memphis, TN, United States of America

Walter D Whybrew